Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.41 |
| ▸ | F10 | P00742 | 6/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12302151 | 0.86 | SIGMAR1 (0.44) | SIGMAR1TMEM97F10PREPAADAT | |
| SCHEMBL12565150 | 0.80 | PRCP (0.45) | SIGMAR1TMEM97 | |
| SCHEMBL6126944 | 0.77 | PRCP (0.51) | — | |
| SCHEMBL2631645 | 0.77 | PRCP (0.51) | — | |
| SCHEMBL13309251 | 0.77 | PRCP (0.51) | — | |
| SCHEMBL8748850 | 0.76 | PRCP (0.52) | — | |
| SCHEMBL14886226 | 0.74 | DGAT1 (0.42) | SIGMAR1TMEM97PREPAADAT | |
| SCHEMBL15372096 | 0.73 | HCRTR1 (0.37) | SIGMAR1TMEM97PREPAADAT | |
| SCHEMBL12683162 | 0.73 | HCRTR1 (0.37) | SIGMAR1TMEM97PREPAADAT | |
| SCHEMBL12332121 | 0.73 | HCRTR1 (0.43) | AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | SIGMAR1 1946/4885TMEM97 1985/4885F10 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.